The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp
SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers
The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The early-stage study will test the drug’s safety, tolerability and biological effects in humans
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
ABBV-295 produced clinically meaningful, dose-dependent weight loss over 12–13 weeks
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
